Ignite Creation Date:
2025-12-24 @ 4:56 PM
Ignite Modification Date:
2025-12-25 @ 2:38 PM
Study NCT ID:
NCT02908750
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2016-08-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-02
Start Date Type:
ACTUAL
Primary Completion Date:
2017-07-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-11
Completion Date Type:
ACTUAL
First Submit Date:
2016-08-23
First Submit QC Date:
None
Study First Post Date:
2016-09-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-10
Last Update Post Date:
2022-11-14
Last Update Post Date Type:
ACTUAL